Company: BDRX
Filing Date: 2025-06-02
Form Type: 424B3
Source: 0001214659-25-008713
Chunk: 4

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-06-02
Form: 424B3
Chunk 4
---
. 2019 Feb; 20(3): 755

The Cancer Prevention and Research Institute of Texas
To date, CPRIT has awarded $2.9 billion in grants to Texas research institutions and organizations through its academic
research, prevention and product development research programs. CPRIT has recruited 237 distinguished researchers, supported the establishment,
expansion or relocation of 43 companies to Texas and generated over $5.7 billion in additional public and private
investment. CPRIT funding has advanced scientific and clinical knowledge and provided 7.4 million life-saving cancer prevention and early
detection services reaching Texans from all 254 counties. On November 5, 2019, Texas voters overwhelmingly approved a constitutional
amendment to provide an additional $3 billion to CPRIT for a total $6 billion investment in cancer research and prevention.
Learn more at https://cprit.texas.gov/.

About Biodexa Pharmaceuticals PLC

Biodexa Pharmaceuticals PLC (listed on NASDAQ: BDRX) is a clinical stage biopharmaceutical
company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs. The Company’s lead
development programs include eRapa, under development for Familial Adenomatous Polyposis and Non-Muscle Invasive Bladder Cancer; tolimidone,
under development for the treatment of type 1 diabetes; and MTX110, which is being studied in aggressive rare/orphan brain cancer indications.

eRapa is a proprietary oral tablet formulation of rapamycin, also known as sirolimus.
Rapamycin is an mTOR (ammalian arget f apamycin) inhibitor. mTOR has been shown to have a significant
role in the signalling pathway that regulates cellular metabolism, growth and proliferation and is activated during tumorigenesis.

Tolimidone is an orally delivered, potent and selective inhibitor of Lyn kinase.
Lyn is a member of the Src family of protein tyrosine kinases, which is mainly expressed in hematopoietic cells, in neural tissues, liver,
and adipose tissue. Tolimidone demonstrates glycaemic control via insulin sensitization in animal models of diabetes and has the potential
to become a first in class blood glucose modulating agent.

MTX110 is a solubilized formulation of the histone deacetylase (HDAC) inhibitor,
panobinostat. This proprietary formulation enables delivery of the product via convection-enhanced delivery (CED) at